Last reviewed · How we verify
NCT05589675: KITCOLO22
Evaluation of a New Invitation Procedure to the French Organized Colorectal Cancer Screening Program
NA trial testing Dispatch of the screening test along the invitation letter to the national colorectal cancer screening program in Colorectal Cancer in 64,500 participants. Participants enrolled and being followed up; not accepting new ones.
17 July 2025
Quick facts
| Lead sponsor | International Agency for Research on Cancer |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 64,500 |
| Start date | 1 April 2023 |
| Primary completion | 17 July 2025 |
| Estimated completion | 27 February 2026 |
| Sites | 3 locations across France |
Drugs / interventions tested
- Dispatch of the screening test along the invitation letter to the national colorectal cancer screening program
- Sending of a prior notification to the new entrants of the national program
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
Sponsor
International Agency for Research on Cancer
Who can join
Adults 50 to 74, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized controlled trial comparing the effect on participation rates to colorectal cancer screening between an intervention arm (invitation letter to the screening program including a FIT test with or without prior notification) and a control arm with the standard of care (invitation letter to visit the GP who will deliver the FIT test).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05589675
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other International Agency for Research on Cancer trials
Trials by the same sponsor.
- NCT07256912 — A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared t · Phase 4 · not yet recruiting
- NCT07193030 — Peer-Led Intervention To Reduce Alcohol Binge Drinking Among University Students In Romania · NA · not yet recruiting
- NCT05286034 — Using Artificial Intelligence-based ChatBot to Improve Women's Participation to Cervical Cancer Screening Programme · NA · recruiting
- NCT06749847 — HPV Self-sampling in the General Population · NA · recruiting
- NCT07407153 — Triaging of Women Detected With a Breast Lump on Clinical Breast Examination Using Portable Ultrasound Device · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05589675 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by International Agency for Research on Cancer
- Last refreshed: 28 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05589675.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing